The 340B Drug Pricing Program was created to help certain healthcare providers buy outpatient drugs at lower prices. These providers are called covered entities and include hospitals with many low-income patients, critical access hospitals, federally qualified health centers (FQHCs), and AIDS drug assistance programs.
Many hospitals save between 20% and 50% on outpatient drugs through this program. According to the Government Accountability Office (GAO), these savings help hospitals give more patients access to medicines, manage medication therapy, and offer important services like opioid treatment and care for chronic diseases. In 2021, hospitals using 340B provided nearly $68 billion in community benefits.
However, the program faces problems like wrong pricing and billing practices. It is also important that drug manufacturers and pharmacies follow all the rules.
One big problem for the 340B program is that some drug manufacturers charge too much or impose illegal limits on contract pharmacies. Covered entities use contract pharmacies to give 340B drugs to qualified patients. But some manufacturers have put rules on these pharmacies that stop them from getting the discounts. This makes hospitals pay more than they should.
The American Hospital Association (AHA) says that Critical Access Hospitals lose over $500,000 each year on average because they are denied 340B prices by contract pharmacies. Disproportionate Share Hospitals lose about $3 million each year on average. These extra costs make it hard for hospitals to run well and serve low-income patients.
Overcharging and limited access also reduce money hospitals have for patient care. Higher drug costs mean hospitals spend more money but don’t get more income. This can force hospitals to cut back on services or limit how many patients they see.
Hospitals and healthcare providers must follow many rules to stay compliant with 340B. They have to watch contract pharmacies, decide how to bill Medicaid patients, and make sure 340B drugs go only to eligible patients. They also need to complete annual recertifications and reviews inside their organization.
The Health Resources and Services Administration (HRSA) runs the program through the Office of Pharmacy Affairs (OPA). HRSA does about 200 audits a year on covered entities. These audits check if contract pharmacies follow rules, if billing is correct, and if other program rules are followed. Since 2012, HRSA has done about 1,720 audits focused on stopping drug diversion and duplicate discounts.
However, drug manufacturers are not audited as much. Manufacturers get about six audits a year. Because of this, problems like overcharging or limiting 340B prices by manufacturers are harder to catch.
The American Hospital Association asks Congress to give HRSA more money so it can audit drug manufacturers more. The AHA also supports a process called Administrative Dispute Resolution (ADR). This process lets covered entities challenge pricing or restrictions from manufacturers, but it has not been fully put into use even though the law approved it over ten years ago.
Pharmacy Benefit Managers (PBMs) cause more problems for 340B. PBMs use pricing and reimbursement rules that reduce the benefits hospitals get from the program. This lowers the money hospitals can use to pay for community health services.
States like California, Minnesota, and Washington have laws to stop PBMs from treating 340B providers unfairly with pricing. But the federal government needs stronger rules to stop PBMs from making patients go to non-340B pharmacies or sending drugs outside the authorized pharmacies. These actions, called “whitebagging” and “brownbagging,” can sometimes be unsafe for patients.
The AHA asks Congress to make clear laws that protect contract pharmacy arrangements. This way, hospitals can trust their pharmacy partnerships and keep serving patients without interference from manufacturers.
The 340B program does not allow duplicate discounts. This means a drug cannot get discounts from more than one federal program, such as Medicaid. Checking this rule is hard because drug claims and prices move through many systems.
A bipartisan bill suggests creating a national data claims clearinghouse. This clearinghouse would track Medicaid claims involving 340B drugs to stop duplicate discounts. It would only collect Medicaid data and protect patient privacy under HIPAA. The goal is to make reporting easier for providers and to make the program clearer.
If passed, this clearinghouse would help covered entities report drug use accurately, lower the risk of mistakes, and save money in the program.
Artificial intelligence (AI) tools can help manage the 340B program better. They can watch drug buying, billing, and giving out drugs in real time. Automated systems can check pharmacy claims against patient eligibility, find possible billing errors, and remind staff about contract pharmacy rules. Automation lowers mistakes from handling 340B records by hand, which can be very tricky.
Using machine learning, AI can find unusual activities that might mean illegal drug diversion or duplicate billing. This helps covered entities stay ready for audits and avoid penalties.
Many tasks tied to 340B compliance, like scheduling yearly recertifications, watching contract pharmacy deals, and keeping audit paperwork, can overwhelm healthcare staff. Workflow automation tools can take care of repeating tasks such as sending appointment reminders, checking patient details, and managing documents. This lets staff spend more time on patient care.
Companies like Simbo AI offer phone automation and answering systems using AI. These tools handle appointment bookings, prescription refill requests, and eligibility questions through automated phone calls. This reduces the load on front desk workers, improves accuracy for 340B tasks, cuts down human mistakes, and helps patients get timely answers.
Putting AI compliance tools and workflow automations into current healthcare information systems (HIS) helps data move smoothly. This means billing, pharmacy, and patient services update automatically and share information easily. This makes the program more transparent and cuts down on management errors.
Centralizing these processes helps covered entities track compliance better, make audit reports quickly, and answer HRSA inquiries fast. This technology supports choices about contract pharmacies and drug buys using real data.
Medical practice administrators and owners in the United States must keep their operations financially healthy while giving good patient care. The 340B program offers important drug cost savings if rules are followed and problems with manufacturers or PBMs are handled well.
The growing complexity around contract pharmacy rules, overcharges, and regulations makes it hard for providers to handle 340B by hand. Mistakes and rule-breaking gaps can lead to costly audits, paying money back, or even losing the program.
Using AI and automation can help healthcare administrators manage compliance and clinical work better. These tools reduce errors, help with tracking, and handle more regulatory information. This lets healthcare providers spend more resources on patient care and community health instead of paperwork.
The 340B program is an important way for many U.S. healthcare providers to help patients in need. Covered entities, lawmakers, and regulators must work together to keep the program fair. They need to fix problems with overcharging, make sure audits are fair, protect contract pharmacies, and use AI tools for better workflows. Doing this helps medical practices use 340B’s savings while keeping their finances and operations stable.
The 340B Drug Pricing Program was created in 1992 by Congress to provide safety-net providers discounts on outpatient drugs, enabling them to extend federal resources to provide more comprehensive services to vulnerable populations.
Eligible entities include various hospitals (e.g., disproportionate share hospitals, critical access hospitals) and non-hospital entities like federally qualified health centers, AIDS drug assistance programs, and more.
The program is administered by the Office of Pharmacy Affairs (OPA) within the Health Resources and Services Administration (HRSA) under HHS.
Entities can apply by completing the online registration process during the first two weeks of any calendar quarter, and approved entities are listed in the 340B OPA Information System.
Covered entities must decide whether to ‘carve in’ or ‘carve out’ 340B drugs for Medicaid fee-for-service patients, ensuring compliance with duplicate discount prohibitions to avoid overcharging.
Compliance is ensured through annual recertification, monitoring contract pharmacies, and establishing criteria for reporting breaches of compliance to HRSA.
Common pitfalls include improper billing practices, failure to monitor contract pharmacies, and inadequate documentation of patient eligibility.
Violating the ceiling price results in penalties, including refunding overcharges and potential civil monetary penalties for knowing violations.
Yes, covered entities can contract with pharmacies but must ensure compliance with 340B requirements, including tracking patient eligibility and preventing diversion.
HRSA conducts audits of covered entities, with approximately 200 audits per year, and manufacturers can also audit but must do so under specific HRSA guidelines.
Simbo is using AI agents to automate all phone related workflows. Connect now to know more.
Schedule AI Agents Demo Now© Since 2019, Simbo AI.
